The present invention relates to a method for preparing methylated amines using carbon dioxide and to the use of the method for manufacturing vitamins, pharmaceutical products, glues, acrylic fibres and synthetic leathers, pesticides and fertilisers. The invention also relates to a method for manufacturing vitamins, pharmaceutical products, glues, acrylic fibres, synthetic leathers, pesticides and fertilisers, including a step of preparing methylated amines by the method according to the invention. The present invention also relates to a method for preparing marked methylated amines and to the uses thereof.

The present invention relates to a method for preparing methylated amines using carbon dioxide and to the use of the method for manufacturing vitamins, pharmaceutical products, glues, acrylic fibres and synthetic leathers, pesticides and fertilisers. The invention also relates to a method for manufacturing vitamins, pharmaceutical products, glues, acrylic fibres, synthetic leathers, pesticides and fertilisers, including a step of preparing methylated amines by the method according to the invention. The present invention also relates to a method for preparing marked methylated amines and to the uses thereof.

There is provided a process for the reduction of one or more amide moieties in a compound comprising contacting the compound with hydrogen gas and a transition metal catalyst in the presence or absence of a base under conditions for the reduction an amide bond. The presently described processes can be performed at low catalyst loading using relatively mild temperature and pressures, and optionally, in the presence or absence of a base or high catalyst loadings using low temperatures and pressures and high loadings of base to effect dynamic kinetic resolution of achiral amides.

There is provided a process for the reduction of one or more amide moieties in a compound comprising contacting the compound with hydrogen gas and a transition metal catalyst in the presence or absence of a base under conditions for the reduction an amide bond. The presently described processes can be performed at low catalyst loading using relatively mild temperature and pressures, and optionally, in the presence or absence of a base or high catalyst loadings using low temperatures and pressures and high loadings of base to effect dynamic kinetic resolution of achiral amides.

A compound represented by the formula:

##STR00001## wherein each R is independently selected from the group consisting of (i) substituted or unsubstituted alkyl with C=0 to 12 inclusive; wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently selected from the group consisting of alkyl, aryl, alkylaryl groups and hydrogen; wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are each independently selected from the group consisting of alkyl, aryl, alkylaryl groups and hydrogen; and wherein one of R.sup.1 and R.sup.2 and one of R.sup.3 and R.sup.4 may optionally be bridged by a polymethylene group to form a cycloalkyl; wherein when C=0 in R, the combined group R.sup.1 R.sup.2 is the same as the combined group R.sup.3 R.sup.4; and wherein when C=1 in R, each of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are hydrogen.

Antidegradant compounds are disclosed, and methods of making them, that are represented by the formula I:

##STR00001## wherein each X is independently selected from the group consisting of ethyl, methyl, or hydrogen.

Also disclosed are diimine intermediates corresponding to formula III:

##STR00002## wherein each X is independently selected from the group consisting of ethyl, methyl, or hydrogen. These intermediates themselves exhibit antidegradant activity.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

The invention relates to a process for producing compounds containing at least one arylamino group by means of a palladium-catalysed coupling reaction of an arylamino compound with an aryl compound, using LiOtBu as a base.

The invention relates to a process for producing compounds containing at least one arylamino group by means of a palladium-catalysed coupling reaction of an arylamino compound with an aryl compound, using LiOtBu as a base.

The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.